Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Should You Buy Novartis Stock Before October 28?
Economy

Should You Buy Novartis Stock Before October 28?

Last updated: October 10, 2025 6:17 pm
Share
Should You Buy Novartis Stock Before October 28?
SHARE

This year, Novartis (NVS), a leading global healthcare firm based in Switzerland, is experiencing robust growth fueled by effective pipeline management, favorable regulatory outcomes, premium licensing agreements, shareholder returns, and positive market perceptions. The company’s stock has increased by 36.3% year-to-date, significantly surpassing overall market performance.

After the 2023 spinoff of Sandoz (SDZNY), Novartis has repositioned itself as a dedicated innovative medicines entity, concentrating on high-value therapeutic sectors.

  • The Chart’s Flashing a New Warning: META Stock Could Tumble to $500 From Here

  • Trump Just Took a 10% Stake in Trilogy Metals. Should You Buy TMQ Stock Here?

  • I Told You How to Trade AMD Stock to $200. Now That It’s an ‘AI Hero,’ Here’s 1 Way to Play Its Next Move.

  • Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won’t find anywhere else.

The announcement of Novartis’ third-quarter earnings report is set for October 28, raising questions about whether the stock is a sound investment prior to the earnings release.

www.barchart.com

www.barchart.com

By concentrating on high-value innovative medicines, Novartis is reaping the rewards. Excluding Entresto, the company’s priority brands saw a 33% increase, suggesting that its new generation of drugs is successfully driving growth. In Q2, net sales jumped 11% year-over-year, with core earnings per share climbing 24% to $2.42.

During the earnings call, CEO Vas Narasimhan highlighted the robust performance of the company’s portfolio, especially its newer oncology, neurology, and cardiovascular offerings as key contributors to its impressive quarter. The oncology medication Kisqali emerged as a standout, surging 64% and achieving total prescription leadership in metastatic breast cancer. Narasimhan indicated that the upward trend of Kisqali suggests it is poised to become a multibillion-dollar growth driver in the coming decade.

See also  Goods, Services, and Tariffs - Econlib

Moreover, Kesimpta, Novartis’ self-administered treatment for multiple sclerosis (MS), rose 33% this quarter. Additionally, Pluvicto for prostate cancer rebounded strongly, increasing 30% post-approval of its new pre-tax indication in the U.S. The cholesterol-lowering medication Leqvio (inclisiran) also recorded an impressive 61% growth trajectory, on pace to exceed $1 billion in annual sales.

Entresto, Novartis’ leading heart failure drug, continues its consistent growth. The company has confirmed an anticipated loss of exclusivity (LoE) by mid-2025 in the U.S., due to ongoing litigation with one generic competitor. However, it remains a substantial global revenue contributor, particularly in Europe, China, and Japan, where patent protection lasts until 2026 and beyond, suggesting ongoing significant revenue generation throughout the decade.

TAGGED:BuyNovartisOctoberStock
Share This Article
Twitter Email Copy Link Print
Previous Article Report: Thune Betrays MAGA, Begs Trump Not to Lay Off Government Employees During Shutdown, Wastes Once-in-a-Lifetime Opportunity Report: Thune Betrays MAGA, Begs Trump Not to Lay Off Government Employees During Shutdown, Wastes Once-in-a-Lifetime Opportunity
Next Article How to Style Knee-High Boots—7 Fall-Ready Outfit Ideas How to Style Knee-High Boots—7 Fall-Ready Outfit Ideas
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Dancing With the Stars One-Hit Wonder Night Scores: Who Went Home?

Dancing With the Stars has kicked off its 34th season with a bang, delivering what…

September 24, 2025

Fans Left Stunned Sabrina Carpenter is a Nepo Baby with a Famous Aunt

Sabrina Carpenter: The Simpsons Connection Sabrina Carpenter rose to fame at a young age, thanks…

June 18, 2025

Xiaomi 15 Release Date, Price & Specs Rumours

The Xiaomi 15 series is generating quite a buzz as users eagerly await the launch…

September 29, 2024

16 Smocked Maxi Dresses on Amazon That Cleverly Conceal Bloat

Smocked maxi dresses are a must-have summer staple that effortlessly combines comfort with style. These…

June 21, 2025

Josh Allen on Marrying Hailee Steinfeld: ‘She Makes Life Easier’

Josh Allen, the star NFL quarterback, recently opened up about his new wife, Hailee Steinfeld,…

June 11, 2025

You Might Also Like

Market analysts react to Trump-Xi meet
Economy

Market analysts react to Trump-Xi meet

October 31, 2025
29 truck carrier files Chapter 11
Economy

29 truck carrier files Chapter 11

October 31, 2025
Trust Government Statistics, Not Government
Economy

Trust Government Statistics, Not Government

October 31, 2025
Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating
Economy

Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?